更年期女性血管舒缩症状(VMS):选择性NK3R拮抗剂MLE-301进入临床试验

2020-09-28 Allan MedSci原创

即将开展选择性神经激肽3受体(NK3R)拮抗剂MLE-301治疗更年期女性的VMS(通常被称为潮热和盗汗)的I期临床试验。

Millendo Therapeutics是一家临床阶段的生物制药公司,该公司近日宣布,即将开展选择性神经激肽3受体(NK3R)拮抗剂MLE-301治疗更年期女性的VMS(通常被称为潮热和盗汗)的I期临床试验。

Millendo Therapeutics总裁兼首席执行官Julia C. Owens说:“我们很高兴将MLE-301推进到临床阶段,这项I期临床试验的结果将使我们进一步了解MLE-301的安全性、PK / PD和功效概况”。

首次人类试验旨在评估MLE-301的安全性和耐受性。该研究的单次上升剂量部分将在健康的男性志愿者中进行,以确定MLE-301的药代动力学及其通过生物标志物(黄体生成激素、睾丸激素)的减少来衡量的药效学特征。多个递增剂量部分将招募绝经后女性,从而可以测量VMS频率和严重程度的降低,并建立初步的临床概念证明。

临床前数据表明,NK3R拮抗剂MLE-301能够显著降低睾丸激素的作用。基于其已证明的体外和体内活性,Millendo认为MLE-301在更年期女性VMS领域可能具有临床影响。

 

原始出处:

https://www.firstwordpharma.com/node/1760190?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2037422, encodeId=b730203e42241, content=<a href='/topic/show?id=e9e289e771c' target=_blank style='color:#2F92EE;'>#血管舒缩症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89777, encryptionId=e9e289e771c, topicName=血管舒缩症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d81c2500028, createdName=12498561m32(暂无昵称), createdTime=Mon Jun 21 04:20:03 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922968, encodeId=9f481922968f0, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Tue Oct 27 05:20:03 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511770, encodeId=21361511e70bb, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Wed Sep 30 01:20:03 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888868, encodeId=30b2888868d8, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1995401099, createdName=ms4000001617780766, createdTime=Mon Sep 28 10:59:34 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888859, encodeId=64e58888598c, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1995401099, createdName=ms4000001617780766, createdTime=Mon Sep 28 10:25:14 CST 2020, time=2020-09-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2037422, encodeId=b730203e42241, content=<a href='/topic/show?id=e9e289e771c' target=_blank style='color:#2F92EE;'>#血管舒缩症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89777, encryptionId=e9e289e771c, topicName=血管舒缩症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d81c2500028, createdName=12498561m32(暂无昵称), createdTime=Mon Jun 21 04:20:03 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922968, encodeId=9f481922968f0, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Tue Oct 27 05:20:03 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511770, encodeId=21361511e70bb, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Wed Sep 30 01:20:03 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888868, encodeId=30b2888868d8, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1995401099, createdName=ms4000001617780766, createdTime=Mon Sep 28 10:59:34 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888859, encodeId=64e58888598c, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1995401099, createdName=ms4000001617780766, createdTime=Mon Sep 28 10:25:14 CST 2020, time=2020-09-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2037422, encodeId=b730203e42241, content=<a href='/topic/show?id=e9e289e771c' target=_blank style='color:#2F92EE;'>#血管舒缩症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89777, encryptionId=e9e289e771c, topicName=血管舒缩症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d81c2500028, createdName=12498561m32(暂无昵称), createdTime=Mon Jun 21 04:20:03 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922968, encodeId=9f481922968f0, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Tue Oct 27 05:20:03 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511770, encodeId=21361511e70bb, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Wed Sep 30 01:20:03 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888868, encodeId=30b2888868d8, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1995401099, createdName=ms4000001617780766, createdTime=Mon Sep 28 10:59:34 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888859, encodeId=64e58888598c, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1995401099, createdName=ms4000001617780766, createdTime=Mon Sep 28 10:25:14 CST 2020, time=2020-09-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2037422, encodeId=b730203e42241, content=<a href='/topic/show?id=e9e289e771c' target=_blank style='color:#2F92EE;'>#血管舒缩症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89777, encryptionId=e9e289e771c, topicName=血管舒缩症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d81c2500028, createdName=12498561m32(暂无昵称), createdTime=Mon Jun 21 04:20:03 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922968, encodeId=9f481922968f0, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Tue Oct 27 05:20:03 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511770, encodeId=21361511e70bb, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Wed Sep 30 01:20:03 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888868, encodeId=30b2888868d8, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1995401099, createdName=ms4000001617780766, createdTime=Mon Sep 28 10:59:34 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888859, encodeId=64e58888598c, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1995401099, createdName=ms4000001617780766, createdTime=Mon Sep 28 10:25:14 CST 2020, time=2020-09-28, status=1, ipAttribution=)]
    2020-09-28 ms4000001617780766

    good

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2037422, encodeId=b730203e42241, content=<a href='/topic/show?id=e9e289e771c' target=_blank style='color:#2F92EE;'>#血管舒缩症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89777, encryptionId=e9e289e771c, topicName=血管舒缩症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d81c2500028, createdName=12498561m32(暂无昵称), createdTime=Mon Jun 21 04:20:03 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922968, encodeId=9f481922968f0, content=<a href='/topic/show?id=78f794e800a' target=_blank style='color:#2F92EE;'>#选择性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94780, encryptionId=78f794e800a, topicName=选择性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0802500050, createdName=肉我只吃一口, createdTime=Tue Oct 27 05:20:03 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511770, encodeId=21361511e70bb, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Wed Sep 30 01:20:03 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888868, encodeId=30b2888868d8, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1995401099, createdName=ms4000001617780766, createdTime=Mon Sep 28 10:59:34 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888859, encodeId=64e58888598c, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1995401099, createdName=ms4000001617780766, createdTime=Mon Sep 28 10:25:14 CST 2020, time=2020-09-28, status=1, ipAttribution=)]
    2020-09-28 ms4000001617780766

    不错

    0